AOC 1001 + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
DM1
Conditions
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Trial Timeline
Oct 28, 2021 → Feb 14, 2023
NCT ID
NCT05027269About AOC 1001 + Placebo
AOC 1001 + Placebo is a phase 1/2 stage product being developed by Avidity Biosciences for DM1. The current trial status is completed. This product is registered under clinical trial identifier NCT05027269. Target conditions include DM1, Myotonic Dystrophy 1, Myotonic Dystrophy.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05027269 | Phase 1/2 | Completed |
Competing Products
6 competing products in DM1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 40 |
| Placebo + AOC 1001 | Avidity Biosciences | Phase 2 | 49 |
| AOC 1001 (del-desiran) + Placebo | Avidity Biosciences | Phase 3 | 74 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 3 | 72 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 1/2 | 36 |